HomeCompareGBS vs NNN

GBS vs NNN: Dividend Comparison 2026

GBS yields 422.65% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBS wins by $17170.29M in total portfolio value
10 years
GBS
GBS
● Live price
422.65%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17170.31M
Annual income
$11,716,925,996.02
Full GBS calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — GBS vs NNN

📍 GBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBSNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBS + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBS pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBS
Annual income on $10K today (after 15% tax)
$35,925.61/yr
After 10yr DRIP, annual income (after tax)
$9,959,387,096.62/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, GBS beats the other by $9,959,384,867.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBS + NNN for your $10,000?

GBS: 50%NNN: 50%
100% NNN50/50100% GBS
Portfolio after 10yr
$8585.17M
Annual income
$5,858,464,309.35/yr
Blended yield
68.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

GBS
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-6.8
Piotroski
5/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBS buys
0
NNN buys
0
No recent congressional trades found for GBS or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBSNNN
Forward yield422.65%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$17170.31M$25.5K
Annual income after 10y$11,716,925,996.02$2,622.67
Total dividends collected$16675.91M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: GBS vs NNN ($10,000, DRIP)

YearGBS PortfolioGBS Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$52,965$42,265.43$10,735$614.96+$42.2KGBS
2$265,889$209,215.55$11,572$708.43+$254.3KGBS
3$1,266,062$981,561.13$12,531$819.53+$1.25MGBS
4$5,722,749$4,368,062.66$13,633$952.29+$5.71MGBS
5$24,575,825$18,452,483.99$14,909$1,111.84+$24.56MGBS
6$100,354,560$74,058,426.77$16,392$1,304.77+$100.34MGBS
7$390,010,320$282,630,940.68$18,129$1,539.52+$389.99MGBS
8$1,443,848,768$1,026,537,725.78$20,173$1,827.08+$1443.83MGBS
9$5,096,622,021$3,551,703,839.84$22,597$2,181.81+$5096.60MGBS
10$17,170,311,559$11,716,925,996.02$25,491$2,622.67+$17170.29MGBS

GBS vs NNN: Complete Analysis 2026

GBSStock

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Full GBS Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this GBS vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBS vs SCHDGBS vs JEPIGBS vs OGBS vs KOGBS vs MAINGBS vs ADCGBS vs EPRTGBS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.